223 related articles for article (PubMed ID: 14728088)
1. Ziprasidone and cognition: the evolving story.
Harvey PD
J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
3. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():19-25. PubMed ID: 14728086
[TBL] [Abstract][Full Text] [Related]
4. Maintaining symptom control: review of ziprasidone long-term efficacy data.
Schooler NR
J Clin Psychiatry; 2003; 64 Suppl 19():26-32. PubMed ID: 14728087
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
6. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
7. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
8. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of ziprasidone: an expanding perspective.
Daniel DG
J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
[TBL] [Abstract][Full Text] [Related]
10. Focus on ziprasidone.
Green B
Curr Med Res Opin; 2001; 17(2):146-50. PubMed ID: 11759185
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
12. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular ziprasidone: moving beyond the conventional in the treatment of acute agitation in schizophrenia.
Brook S
J Clin Psychiatry; 2003; 64 Suppl 19():13-8. PubMed ID: 14728085
[TBL] [Abstract][Full Text] [Related]
14. Introduction. Ziprasidone in schizophrenia: from acute treatment to long-term management.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 19():3-5. PubMed ID: 14728083
[No Abstract] [Full Text] [Related]
15. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone.
Kuwilsky A; Krumm B; Englisch S; Dressing H; Zink M
Pharmacopsychiatry; 2010 Aug; 43(6):216-20. PubMed ID: 20589598
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
[TBL] [Abstract][Full Text] [Related]
18. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
[TBL] [Abstract][Full Text] [Related]
19. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
20. The effects of clozapine on cognitive functioning in schizophrenia.
McGurk SR
J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
